Quarterly ResultMay 15, 2026, 08:12 AM
BioCardia Q1 Net Loss Narrows to $2.26M; Going Concern Warning Issued
AI Summary
BioCardia, Inc. reported a net loss of $2.26 million for the first quarter of 2026, an improvement from $2.71 million in the same period last year. However, the company's cash and cash equivalents significantly declined to $951,000 as of March 31, 2026, leading management to issue a going concern warning, stating current funds are insufficient beyond June 2026. Despite financial challenges, BioCardia made progress in its clinical programs, with Japan's PMDA indicating sufficient evidence for market clearance of CardiAMP Cell Therapy and the US FDA confirming the PMA pathway while recommending continuation of the CardiAMP HF II trial.
Key Highlights
- Net loss for Q1 2026 was $2.26 million, an improvement from $2.71 million in Q1 2025.
- Cash and cash equivalents decreased to $951,000 as of March 31, 2026, from $2.50 million at Dec 31, 2025.
- Management issued a going concern warning, stating cash is insufficient beyond June 2026.
- Total current assets were $1.14 million, while total current liabilities were $2.78 million as of March 31, 2026.
- Research and development expenses decreased to $1.24 million from $1.53 million year-over-year.
- Japan's PMDA indicated CardiAMP Cell Therapy evidence is likely sufficient for market clearance.
- US FDA confirmed Premarket Approval (PMA) pathway and recommended continuing CardiAMP HF II trial.
- Sold 184,725 common shares for $225,000 gross proceeds under ATM in Q1 2026.
Price Impact
More from BCDA